MiR‐429 suppresses proliferation and invasion of breast cancer via inhibiting the Wnt/β‐catenin signaling pathway

Abstract

Background microRNAs ( miRNAs) have been verified as molecular targets for regulating tumor proliferation, invasion, and metastasis in tumor progression. However, the relationship between miRNAs and cellular energy metabolism in breast cancer still needs to be clarified. This study aimed to investigate the role of miR‐429 in breast cancer progression. Methods Bioinformatic analyses were employed to detect the relationship between miR‐429 and cancer‐related signaling pathways. We used a Kaplan‐Meier curve to analyze survival rate in patients with high or low expression of miR‐429. We used real‐time quantitative PCR (RT‐qPCR) to detect the expression of miR‐429 in different cell lines. Sh‐con, over‐miR‐429, miR‐429 inhibitor, and sh‐inhibitor control were transfected. Colony formation and EDU assay were used to detect the proliferation of transfected cells. Wound healing and transwell assays were performed to detect the mobility and invasion ability of transfected cells. Western blot assay was used to detect relative protein expression in transfected cells and different tissues. Bioinformatic analyses were conducted to detect the target proteins expression in different breast cancer databases. Dual luciferase reporter assay was used to confirm the binding site between miR‐429 and fibronectin 1 (FN1). Results The results of our study indicate that MiR‐429 and its target genes are associated with cancer‐related signaling pathways and that higher miR‐429 expression corresponds with a better prognosis. When miR‐429 was overexpressed, the proliferation, invasion of MDA‐MB‐231 were inhibited. MiR‐429 was able to suppress the Wnt/β‐catenin signaling pathway, and FN1 overexpression could rescue the influence of over‐miR‐429. Conclusions The results of our study suggest that miR‐429 suppresses the proliferation and invasion of breast cancer via inhibiting the Wnt/β‐catenin signaling pathway.

MUC14-Related ncRNA-mRNA Network in Breast Cancer

“…In our study, MUC14 was significantly downregulated in breast cancer, possessed statistical ability to distinguish breast cancer tissues from normal breast tissues and its downregulation indicated poor prognosis in breast cancer. Previous investigations also showed that MUC14 was a prognostic biomarker for several types of human cancer, including hepatocellular carcinoma [22], gastric cancer [23], diffuse type gastric cancer [24] and clear cell renal cell carcinoma [25]. To date, no research regarding expression, diagnosis and prognosis of MUC14 in breast cancer has been reported.…”

LncRNA LINC01303 Promotes the Progression of Oral Squamous Cell Carcinomas via the miR-429/ZEB1/EMT Axis

“…MiR-429 has a tumor-promotion role in some cancers. However, miR-429 appears to have a tumor-suppressing role in many cancers, including breast cancer [ 32 ], bladder cancer [ 33 ], and thyroid cancer [ 34 ]. The inhibition of miR-429 could suppress the proliferation, migration, and invasion of cancer cells.…”

MicroRNAs: Emerging Regulators of Metastatic Bone Disease in Breast Cancer

“…Opposing results were observed when cells were transfected with miR-1976 mimics, and the authors attributed a reduced presence of lung metastasis in vivo to miR-1976-induced alterations in EMT and the CSC pool [60]. Similarly, miR-429 has been shown to reduce proliferation, migration, and invasion, as well as EMT, in breast cancer cells in vitro and to inhibit bone metastasis in vivo [62]. A reduced invasion capacity was also observed in the MDA-B02 bone metastatic breast cancer cell line upon overexpression of miR-30b-d, miR-30b-c, or miR-30a-b-c-d-e [63].…”

“…Regarding breast cancer and metastatic bone disease, several in vivo studies demonstrated miRNA-mediated effects on the bone microenvironment leading to reduced tumor growth and attenuated osteolytic disease. For example, high levels of miR-30 [63], miR-124 [46], miR-192 [31], and miR-429 [62] have been shown to have a beneficial effect with reduced osteolysis in vivo. In addition to osteolytic lesions, the frequency of bone metastasis or tumor burden in general can be altered by differential miRNA expression.…”